Show simple item record

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

dc.contributor.authorAletaha, Danielen_US
dc.contributor.authorNeogi, Tuhinaen_US
dc.contributor.authorSilman, Alan J.en_US
dc.contributor.authorFunovits, Juliaen_US
dc.contributor.authorFelson, David T.en_US
dc.contributor.authorBingham, Clifton O.en_US
dc.contributor.authorBirnbaum, Neal S.en_US
dc.contributor.authorBurmester, Gerd R.en_US
dc.contributor.authorBykerk, Vivian P.en_US
dc.contributor.authorCohen, Marc D.en_US
dc.contributor.authorCombe, Bernarden_US
dc.contributor.authorCostenbader, Karen H.en_US
dc.contributor.authorDougados, Maximeen_US
dc.contributor.authorEmery, Paulen_US
dc.contributor.authorFerraccioli, Gianfrancoen_US
dc.contributor.authorHazes, Johanna M. W.en_US
dc.contributor.authorHobbs, Kathrynen_US
dc.contributor.authorHuizinga, Tom W. J.en_US
dc.contributor.authorKavanaugh, Arthur F.en_US
dc.contributor.authorKay, Jonathanen_US
dc.contributor.authorKvien, Tore K.en_US
dc.contributor.authorLaing, Timothy J.en_US
dc.contributor.authorMease, Philip J.en_US
dc.contributor.authorMénard, Henri A.en_US
dc.contributor.authorMoreland, Larry W.en_US
dc.contributor.authorNaden, Raymond L.en_US
dc.contributor.authorPincus, Theodoreen_US
dc.contributor.authorSmolen, Josef S.en_US
dc.contributor.authorStanislawska-Biernat, Ewaen_US
dc.contributor.authorSymmons, Deborahen_US
dc.contributor.authorTak, Paul P.en_US
dc.contributor.authorUpchurch, Katherine S.en_US
dc.contributor.authorVencovský, Jiríen_US
dc.contributor.authorWolfe, Fredericken_US
dc.contributor.authorHawker, Gillianen_US
dc.date.accessioned2010-10-06T14:53:47Z
dc.date.available2011-03-01T16:26:41Zen_US
dc.date.issued2010-09en_US
dc.identifier.citationAletaha, Daniel; Neogi, Tuhina; Silman, Alan J.; Funovits, Julia; Felson, David T.; Bingham, Clifton O.; Birnbaum, Neal S.; Burmester, Gerd R.; Bykerk, Vivian P.; Cohen, Marc D.; Combe, Bernard; Costenbader, Karen H.; Dougados, Maxime; Emery, Paul; Ferraccioli, Gianfranco; Hazes, Johanna M. W.; Hobbs, Kathryn; Huizinga, Tom W. J.; Kavanaugh, Arthur; Kay, Jonathan; Kvien, Tore K.; Laing, Timothy; Mease, Philip; MÉnard, Henri A.; Moreland, Larry W.; Naden, Raymond L.; Pincus, Theodore; Smolen, Josef S.; Stanislawska-Biernat, Ewa; Symmons, Deborah; Tak, Paul P.; Upchurch, Katherine S.; VencovskÝ, JirÍ; Wolfe, Frederick; Hawker, Gillian (2010). "2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative." Arthritis & Rheumatism 62(9): 2569-2581. <http://hdl.handle.net/2027.42/78045>en_US
dc.identifier.issn0004-3591en_US
dc.identifier.issn1529-0131en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/78045
dc.description.abstractObjective The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA. Methods A joint working group from the ACR and the European League Against Rheumatism developed, in 3 phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease—this being the appropriate current paradigm underlying the disease construct “rheumatoid arthritis.” Results In the new criteria set, classification as “definite RA” is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0–5), serologic abnormality (score range 0–3), elevated acute-phase response (score range 0–1), and symptom duration (2 levels; range 0–1). Conclusion This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimize the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct “rheumatoid arthritis.”en_US
dc.format.extent189046 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.title2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiativeen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationotherMedical University of Vienna, Vienna, Austria ; Dr. Aletaha has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, UCB, Schering-Plough, Wyeth, and Roche (less than $10,000 each).en_US
dc.contributor.affiliationotherBoston University School of Medicine, Boston, Massachusettsen_US
dc.contributor.affiliationotherArthritis Research UK, Chesterfield, UK ; Arthritis Research UK, Copeman House, Chesterfield S41 7TD, UKen_US
dc.contributor.affiliationotherMedical University of Vienna, Vienna, Austriaen_US
dc.contributor.affiliationotherBoston University School of Medicine, Boston, Massachusettsen_US
dc.contributor.affiliationotherJohns Hopkins University, Baltimore, Maryland ; Dr. Bingham has received consulting fees, speaking fees, and/or honoraria from UCB, Roche, Genentech, Celgene, and Merck Serono (less than $10,000 each); he has received research and/or educational grant support from Bristol-Myers Squibb, Genentech, UCB, Centocor, Abbott, and Amgen.en_US
dc.contributor.affiliationotherCalifornia Pacific Medical Center and University of California, San Francisco ; Dr. Birnbaum has received consulting fees, speaking fees, and/or honoraria from Amgen, Pfizer, Centocor, Abbott, and UCB (less than $10,000 each).en_US
dc.contributor.affiliationotherCharitÉ Hospital–University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany ; Dr. Burmester has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, Pfizer, UCB, and Roche (less than $10,000 each).en_US
dc.contributor.affiliationotherMount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada ; Dr. Bykerk has received consulting fees, speaking fees, and/or honoraria from Amgen, Wyeth, Abbott, Schering-Plough, Roche, Bristol-Myers Squibb, and UCB (less than $10,000 each); her spouse is employed by Genzyme and owns stock in the company.en_US
dc.contributor.affiliationotherNational Jewish Medical and Research Center, Denver, Colorado ; Dr. Cohen has received consulting fees, speaking fees, and/or honoraria from UCB, Genentech, Bristol-Myers Squibb, and Human Genome Sciences (less than $10,000 each).en_US
dc.contributor.affiliationotherLapeyronie Hospital and Montpellier I University, Montpellier, France ; Dr. Combe has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, Pfizer, Roche, Schering-Plough, and Merck, Sharpe, and Dohme (less than $10,000 each).en_US
dc.contributor.affiliationotherBrigham and Women's Hospital and Harvard University, Boston, Massachusettsen_US
dc.contributor.affiliationotherCochin Hospital, Assistance Publique HÔpitaux de Paris, and Paris-Descartes University, Paris, Franceen_US
dc.contributor.affiliationotherUniversity of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK ; Dr. Emery has received consulting fees, speaking fees, and/or honoraria from Pfizer, Abbott, Centocor, UCB, Roche, Bristol-Myers Squibb, and Merck, Sharpe, and Dohme (less than $10,000 each).en_US
dc.contributor.affiliationotherSchool of Medicine, Catholic University of the Sacred Heart, Rome, Italy ; Dr. Ferraccioli holds a patent for T cell receptor clonotype analysis (PCT/IB 2008/053152 NP).en_US
dc.contributor.affiliationotherErasmus Medical Center, University Medical Center Rotterdam, and University of Rotterdam, Rotterdam, The Netherlandsen_US
dc.contributor.affiliationotherUniversity of Colorado School of Medicine, Denveren_US
dc.contributor.affiliationotherLeiden University Medical Centre, Leiden, The Netherlands ; Dr. Huizinga has received consulting fees, speaking fees, and/or honoraria from Schering-Plough, Bristol-Myers Squibb, UCB, Biotest AG, Wyeth/Pfizer, Novartis, Roche, Sanofi-Aventis, Abbott, and Axis-Shield (less than $10,000 each).en_US
dc.contributor.affiliationotherUniversity of California, San Diego ; Dr. Kavanaugh has conducted clinical research for Amgen, Abbott, Bristol-Myers Squibb, UCB, Roche, Centocor, Genentech, and Sanofi-Aventis.en_US
dc.contributor.affiliationotherUMassMemorial Medical Center and University of Massachusetts Medical School, Worcester ; Dr. Kay has received consulting fees from Array BioPharma, Bristol-Myers Squibb, Celgene, Centocor, Genentech, Roche, UCB, and Sanofi-Aventis (less than $10,000 each).en_US
dc.contributor.affiliationotherDiakonhjemmet Hospital, Oslo, Norwayen_US
dc.contributor.affiliationotherSwedish Medical Center and University of Washington, Seattle ; Dr. Mease has received consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Roche, Genentech, UCB, Pfizer, Novartis, and Eli Lilly (less than $10,000 each).en_US
dc.contributor.affiliationotherMcGill University Health Centre and McGill University, Montreal, Quebec, Canada ; Dr. MÉnard has received unrestricted educational and research grants as well as consulting and speaking fees from Abbott, Amgen, Inova, Merck, Pfizer, Roche, Schering-Plough, UCB, and Wyeth (less than $10,000 each) and investigator-initiated research grants from Bristol-Myers Squibb, EuroImmun AG, and Roche (more than $10,000 each); he owns stock or stock options in Merck; and he has a license agreement with EuroImmun AG for an anti-Sa enzyme-linked immunosorbent assay.en_US
dc.contributor.affiliationotherUniversity of Pittsburgh, Pittsburgh, Pennsylvania ; Dr. Moreland has received consulting fees, speaking fees, and/or honoraria from Biogen Idec, Centocor, Pfizer, Takeda, KaloBios, ChemoCentryx, UCB, Genentech, Incyte, and Eli Lilly (less than $10,000 each).en_US
dc.contributor.affiliationotherMinistry of Health, Auckland, New Zealand ; Dr. Naden has received consulting fees from the American College of Rheumatology in regard to the methodology of developing weighted scoring systems (more than $10,000).en_US
dc.contributor.affiliationotherNew York University Hospital for Joint Diseases, New York, New York ; Dr. Pincus has received consulting fees, speaking fees, and/or honoraria from Amgen, Abbott, Bristol-Myers Squibb, Centocor, UCB, Wyeth, and Genentech (less than $10,000 each) and investigator-initiated research grants from Amgen, Bristol-Myers Squibb, UCB, and Centocor.en_US
dc.contributor.affiliationotherMedical University of Vienna, Vienna, Austriaen_US
dc.contributor.affiliationotherInstitute of Rheumatology, Warsaw, Poland ; Dr. Stanislawska-Biernat has received speaking fees from Abbott and Pfizer (less than $10,000 each).en_US
dc.contributor.affiliationotherUniversity of Manchester, Manchester, UKen_US
dc.contributor.affiliationotherAcademic Medical Center, University of Amsterdam, Amsterdam, The Netherlandsen_US
dc.contributor.affiliationotherUMassMemorial Medical Center and University of Massachusetts Medical School, Worcesteren_US
dc.contributor.affiliationotherInstitute of Rheumatology, Prague, Czech Republic ; Dr. VencovskÝ has received speaking fees from Pfizer, UCB, Abbott, Roche, and Merck, Sharpe, and Dohme (less than $10,000 each).en_US
dc.contributor.affiliationotherNational Data Bank for Rheumatic Diseases and University of Kansas, Wichitaen_US
dc.contributor.affiliationotherWomen's College Hospital and University of Toronto, Toronto, Ontario, Canadaen_US
dc.identifier.pmid20872595en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/78045/1/27584_ftp.pdf
dc.identifier.doi10.1002/art.27584en_US
dc.identifier.sourceArthritis & Rheumatismen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.